2017
Overview
Posttransplant lymphoproliferative disease (PTLD) is an uncommon but potentially dangerous complication of organ transplantation. It is a type of cancer that develops in the lymphoid cells of the immune system and is characterized by the uncontrolled growth of these cells. The condition is caused by the transplant recipient's weakened immune system, which allows the virus that usually causes Epstein-Barr virus (EBV) infection to overgrow. Treatment of PTLD usually involves the use of chemotherapy, immunosuppression, and/or radiation therapy. Early detection and treatment of not only the virus, but also the underlying cause of the transplanted organ failure, is essential in order to treat the condition. As such, understanding the signs, symptoms, and risk factors of PTLD is essential in order to improve patient outcomes. Additionally, research into the development of new treatments and improved transplant techniques to reduce the risk of PTLD is ongoing.
Research published in this journal
1 peer-reviewed article, ranked by relevance. Each links to its DOI.